Completed PHASE3 INTERVENTIONAL 2-arm NCT00320359

Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer

Sponsor: GlaxoSmithKline

Conditions Lung Cancer, Small Cell

Interventions Intravenous etoposide/cisplatin Intravenous topotecan/cisplatin

Updated 7 times since 2017 Last updated: Feb 27, 2017 Started: Aug 31, 2002 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lung Cancer, Small Cell, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Mar 2017 [monthly]

Completed PHASE3

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bayreuth, Germany , Berlin, Germany , Bielefeld, Germany , Bludesch, Austria , Bochum, Germany , Bonn, Germany , Borstel, Germany , Bremen, Germany , Chemnitz, Germany , Coesfeld, Germany and 54 more locations